General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Baudax Bio Announces Corporate Update | globenewswire.com • |
Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag | zacks.com • |
Why Is Baudax Bio (BXRX) Stock Up 75% Today? | investorplace.com • |
Baudax Bio shares rocket as lead clinical candidate gains FDA orphan drug designation | proactiveinvestors.com • |
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors | globenewswire.com • |
Here's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock Now | zacks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-03-07 | 2023-12 | -0.12 | N/A | N/A | N/A |
2023-11-20 | 2023-09 | -0.53 | N/A | N/A | N/A |
2023-08-16 | 2023-06 | -2.04 | N/A | N/A | N/A |
2023-05-12 | 2023-03 | 5.75 | N/A | N/A | N/A |
2023-02-23 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-08 | 2022-09 | -21.2 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-01-02 | Noble Capital Markets | Downgrade | Outperform | Market Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-06-14 | ASHTON WILLIAM L | Director | 42.53K | Stock Award(Grant) |
2022-06-14 | BASKIES ARNOLD M | Director | 41.94K | Stock Award(Grant) |
2022-06-14 | CHURCHILL WINSTON J. JR. | Director | 46.82K | Stock Award(Grant) |
2022-06-14 | DILMORE JILLIAN | Officer | 15.74K | Stock Award(Grant) |
2022-06-14 | DRECHSLER ANDREW T | Director | 41.66K | Stock Award(Grant) |
2022-12-14 | HENWOOD GERALDINE A | Chief Executive Officer | 2.44K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Creative Planning | 45.00K | 52.65K | 0.49% |
2023-06-29 | Jane Street Group, LLC | 27.34K | 31.99K | 0.30% |
2023-06-29 | Vanguard Group Inc | 24.90K | 29.13K | 0.27% |
2023-06-29 | State Street Corporation | 11.60K | 13.57K | 0.13% |
2023-06-29 | Tower Research Capital LLC (TRC) | 10.56K | 12.35K | 0.12% |
2023-06-29 | UBS Group AG | 9.66K | 11.30K | 0.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 24.90K | 29.13K | 0.27% |
2023-05-30 | Fidelity Extended Market Index Fund | 919.00 | 482.00 | 0.01% |
Split | Date |
---|---|
1 : 40 | 2022-12-01 |
1 : 35 | 2022-02-16 |
$BXRX what a scam after six days…..I’m out! Moving to $MULN.
$BXRX big news coming out…..reason for halt. Will open above $5 now…..
$BXRX float has been covered next $4
$BXRX what the hell is going on. We have more volume than Kala and nothing?
$BXRX this is unreal……so much for power hour
$BXRX been dropping all day…..what a mistake
$BXRX how in the world do we have volume like what we show and not be over $5 yet?
$BXRX told you…..hit $3.68 and right back down
$BXRX think about at the stop losses just triggered because of the $2.30 dip. I mean really…..
$BXRX how does this dip to $2.30 then back to $3.40? Manipulation at its finest I see!!
$BXRX with all this volume still able to go down?? What the F’d!!
$BXRX have we hit $3.68 for the fifth time so we can go down again…..come on already run!!
$BXRX pure BS going on right now….
$BXRX shorts about to get squeezed pretty quickly here….